{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:40:08Z","timestamp":1749948008301,"version":"3.41.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Lopinavir\/ritonavir plasma concentrations are profoundly reduced when co-administered with rifampicin. Super-boosting of lopinavir\/ritonavir is limited by nonavailability of single-entity ritonavir, while double-dosing of co-formulated lopinavir\/ritonavir given twice-daily produces suboptimal lopinavir concentrations in young children. We evaluated whether increased daily dosing with modified 8-hourly lopinavir\/ritonavir 4:1 would maintain therapeutic plasma concentrations of lopinavir in children living with HIV receiving rifampicin-based antituberculosis treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Children with HIV\/tuberculosis coinfection weighing 3.0 to 19.9\u2009kg, on rifampicin-based antituberculosis treatment were commenced or switched to 8-hourly liquid lopinavir\/ritonavir 4:1 with increased daily dosing using weight-band dosing approach. A standard twice-daily dosing of lopinavir\/ritonavir was resumed 2 weeks after completing antituberculosis treatment. Plasma sampling was conducted during and 4 weeks after completing antituberculosis treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of 20 children enrolled; 15, 1\u20137 years old, had pharmacokinetics sampling available for analysis. Lopinavir concentrations (median [range]) on 8-hourly lopinavir\/ritonavir co-administered with rifampicin (n = 15; area under the curve<jats:sub>0\u201324<\/jats:sub> 55.32\u2009mg\/h\/L [0.30\u2013398.7\u2009mg\/h\/L]; C<jats:sub>max<\/jats:sub> 3.04\u2009mg\/L [0.03\u201318.6\u2009mg\/L]; C<jats:sub>8hr<\/jats:sub> 0.90\u2009mg\/L [0.01\u201313.7\u2009mg\/L]) were lower than on standard dosing without rifampicin (n = 12; area under the curve<jats:sub>24<\/jats:sub> 121.63\u2009mg\/h\/L [2.56\u2013487.3\u2009mg\/h\/L]; C<jats:sub>max<\/jats:sub> 9.45\u2009mg\/L [0.39\u201326.4\u2009mg\/L]; C<jats:sub>12hr<\/jats:sub> 3.03\u2009mg\/L [0.01\u201317.7\u2009mg\/L]). During and after rifampicin cotreatment, only 7 of 15 (44.7%) and 8 of 12 (66.7%) children, respectively, achieved targeted pre-dose lopinavir concentrations \u22651mg\/L.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Modified 8-hourly dosing of lopinavir\/ritonavir failed to achieve adequate lopinavir concentrations with concurrent antituberculosis treatment. The subtherapeutic lopinavir exposures on standard dosing after antituberculosis treatment are of concern and requires further evaluation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004047","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T20:00:07Z","timestamp":1690574407000},"page":"899-904","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Inadequate Lopinavir Concentrations With Modified 8-Hourly Lopinavir\/Ritonavir 4:1 Dosing During Rifampicin-based Tuberculosis Treatment in Children Living With HIV"],"prefix":"10.1097","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5551-5752","authenticated-orcid":false,"given":"Chishala","family":"Chabala","sequence":"first","affiliation":[{"name":"Department of Paediatrics, University of Zambia, School of Medicine, Lusaka, Zambia"},{"name":"Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Faculty of Health Sciences, Cape Town, South Africa"},{"name":"University Teaching Hospital-Children\u2019s Hospital, Lusaka, Zambia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7008-4145","authenticated-orcid":false,"given":"Anna","family":"Turkova","sequence":"additional","affiliation":[{"name":"Medical Research Council\u2013Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Kapasa","sequence":"additional","affiliation":[{"name":"University Teaching Hospital-Children\u2019s Hospital, Lusaka, Zambia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"LeBeau","sequence":"additional","affiliation":[{"name":"Medical Research Council\u2013Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chimuka H.","family":"Tembo","sequence":"additional","affiliation":[{"name":"University Teaching Hospital-Children\u2019s Hospital, Lusaka, Zambia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Zimba","sequence":"additional","affiliation":[{"name":"University Teaching Hospital-Children\u2019s Hospital, Lusaka, Zambia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lubbe","family":"Weisner","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Faculty of Health Sciences, Cape Town, South Africa"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-2784","authenticated-orcid":false,"given":"Khozya","family":"Zyambo","sequence":"additional","affiliation":[{"name":"University Teaching Hospital-Children\u2019s Hospital, Lusaka, Zambia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4040-1522","authenticated-orcid":false,"given":"Louise","family":"Choo","sequence":"additional","affiliation":[{"name":"Medical Research Council\u2013Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6076-5011","authenticated-orcid":false,"given":"Chalilwe","family":"Chungu","sequence":"additional","affiliation":[{"name":"University Teaching Hospital-Children\u2019s Hospital, Lusaka, Zambia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joyce","family":"Lungu","sequence":"additional","affiliation":[{"name":"University Teaching Hospital-Children\u2019s Hospital, Lusaka, Zambia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1843-8169","authenticated-orcid":false,"given":"Veronica","family":"Mulenga","sequence":"additional","affiliation":[{"name":"University Teaching Hospital-Children\u2019s Hospital, Lusaka, Zambia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6174-8747","authenticated-orcid":false,"given":"Angela","family":"Crook","sequence":"additional","affiliation":[{"name":"Medical Research Council\u2013Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9738-5490","authenticated-orcid":false,"given":"Diana","family":"Gibb","sequence":"additional","affiliation":[{"name":"Medical Research Council\u2013Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, London, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0982-6226","authenticated-orcid":false,"given":"Helen","family":"McIlleron","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Faculty of Health Sciences, Cape Town, South Africa"},{"name":"Wellcome Centre for Infectious Diseases Research in Africa (CIDRI-Africa), Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the SHINE trial team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2334-14-S1-S5","article-title":"Tuberculosis and HIV co-infection in children.","volume":"14","author":"Venturini","year":"2014","journal-title":"BMC Infect Dis"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1080\/14656566.2017.1309023","article-title":"Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.","volume":"18","author":"Rabie","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1128\/AAC.48.5.1553-1560.2004","article-title":"Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers.","volume":"48","author":"la Porte","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"journal-title":"Lancet HIV","article-title":"Lopinavir-ritonavir super-boosting in young HIV-infected children on rifampicin-based tuberculosis therapy compared with lopinavir-ritonavir without rifampicin: a pharmacokinetic modelling and clinical study","author":"Rabie","key":"R5-20250614"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"e32173","DOI":"10.1371\/journal.pone.0032173","article-title":"The safety, effectiveness and concentrations of adjusted lopinavir\/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy.","volume":"7","author":"Decloedt","year":"2012","journal-title":"PLoS One"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3851\/IMP1757","article-title":"Lopinavir exposure is insufficient in children given double doses of lopinavir\/ritonavir during rifampicin-based treatment for tuberculosis.","volume":"16","author":"McIlleron","year":"2011","journal-title":"Antivir Ther"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"e627","DOI":"10.1016\/S2352-3018(22)00160-6","article-title":"Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.","volume":"9","author":"Turkova","year":"2022","journal-title":"Lancet HIV"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3851\/IMP1915","article-title":"Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected children.","volume":"17","author":"Zhang","year":"2012","journal-title":"Antivir Ther"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1093\/jac\/dkz171","article-title":"Pharmacokinetics of adjusted-dose 8-hourly lopinavir\/ritonavir in HIV-infected children co-treated with rifampicin.","volume":"74","author":"Rabie","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s13063-018-2608-5","article-title":"Shorter treatment for minimal tuberculosis (TB) in children (SHINE): a study protocol for a randomised controlled trial.","volume":"19","author":"Chabala","year":"2018","journal-title":"Trials"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1097\/QAI.0b013e3181642257","article-title":"Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis.","volume":"47","author":"Ren","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1097\/INF.0000000000000603","article-title":"The effect of malnutrition on the pharmacokinetics and virologic outcomes of lopinavir, efavirenz and nevirapine in food insecure HIV-infected children in Tororo, Uganda.","volume":"34","author":"Bartelink","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/INF.0000000000001867","article-title":"Population pharmacokinetics of lopinavir in severely malnourished HIV-infected children and the effect on treatment outcomes.","volume":"37","author":"Archary","year":"2018","journal-title":"Pediatr Infect Dis J"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/INF.0000000000003055","article-title":"Pharmacokinetics and safety of zidovudine, lamivudine, and Lopinavir\/Ritonavir in HIV-infected children with severe acute malnutrition in Sub-Saharan Africa: IMPAACT Protocol P1092.","volume":"40","author":"Owor","year":"2021","journal-title":"Pediatr Infect Dis J"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/QAI.0000000000000135","article-title":"The pharmacokinetics and acceptability of lopinavir\/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.","volume":"66","author":"Musiime","year":"2014","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1002\/jcph.1293","article-title":"Population pharmacokinetics of lopinavir\/ritonavir: changes across formulations and human development from infancy through adulthood.","volume":"58","author":"Yang","year":"2018","journal-title":"J Clin Pharmacol"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/bcp.14230","article-title":"Influence of SLCO1B1 polymorphisms on lopinavir Ctrough in Serbian HIV\/AIDS patients.","volume":"86","author":"Dragovic","year":"2020","journal-title":"Br J Clin Pharmacol"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1177\/135965350701200405","article-title":"Plasma concentrations of the HIV-protease inhibitor lopinavir are suboptimal in children aged 2 years and below.","volume":"12","author":"Verweel","year":"2007","journal-title":"Antivir Ther"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3851\/IMP3054","article-title":"Acceptability of lopinavir\/r pellets (minitabs), tablets and syrups in HIV-infected children.","volume":"21","author":"Kekitiinwa","year":"2016","journal-title":"Antivir Ther"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:04:38Z","timestamp":1749945878000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004047","relation":{},"ISSN":["0891-3668"],"issn-type":[{"type":"print","value":"0891-3668"}],"subject":[],"published":{"date-parts":[[2023,7,20]]}}}